Tifacogin

 

Topic mentions per year

Topic mentions per year

1999-2011
01219992011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
RATIONALE Severe community-acquired pneumonia (sCAP) is a leading cause of death worldwide. Adjunctive therapies for sCAP are… (More)
Is this relevant?
Review
2009
Review
2009
INTRODUCTION The purpose of this analysis was to determine the potential efficacy of recombinant human tissue factor pathway… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Review
2004
Review
2004
PURPOSE OF REVIEW An update on recent developments in diagnosis and treatment of disseminated intravascular coagulation. RECENT… (More)
  • table 1
Is this relevant?
Highly Cited
2003
Highly Cited
2003
CONTEXT The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis… (More)
Is this relevant?
2003
2003
SYSTEMIC ACTIVATION OF COAGUlation and thrombus formation in the microvasculature accompanies organ dysfunction and excess… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2002
2002
Tifacogin is a recombinant tissue factor pathway inhibitor (rTFPI) under development by Pharmacia Corp (formerly GD Searle) and… (More)
Is this relevant?
Review
2001
Review
2001
Tissue factor (TF) is the essential cofactor for the coagulation protease factor VIIa (FVIIa), initiating the coagulation cascade… (More)
Is this relevant?